BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng LN, Guo FQ, Li ZS, Wang Z, Ma JH, Wang T, Wei JF, Zhang WW. Dexmedetomidine protects against lidocaine-induced neurotoxicity through SIRT1 downregulation-mediated activation of FOXO3a. Hum Exp Toxicol 2020;39:1213-23. [PMID: 32228195 DOI: 10.1177/0960327120914971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Jain A, Lamperti M, Doyle DJ. Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units. Br J Anaesth 2021;126:e35-8. [PMID: 33190859 DOI: 10.1016/j.bja.2020.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Unchiti K, Leurcharusmee P, Samerchua A, Pipanmekaporn T, Chattipakorn N, Chattipakorn SC. The potential role of dexmedetomidine on neuroprotection and its possible mechanisms: Evidence from in vitro and in vivo studies. Eur J Neurosci 2021;54:7006-47. [PMID: 34561931 DOI: 10.1111/ejn.15474] [Reference Citation Analysis]
3 Xu S, Gao R, Chen L. Dexmedetomidine regulates sevoflurane-induced neurotoxicity through the miR-330-3p/ULK1 axis. J Biochem Mol Toxicol 2021;:e22919. [PMID: 34590382 DOI: 10.1002/jbt.22919] [Reference Citation Analysis]